Successful Phase One Demonstrates Tumor Response With Increased Overall Survival for Lead VBL Therapeutics Compound in Cancer
5/16/2013 12:01:38 PM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of Ph1 data for VB-111 in the journal of Clinical Cancer Research. The manuscript reports a first in man clinical trial of VB-111, VBL’s lead anti-angiogenic Virotherapy candidate, demonstrating its safety and tolerability in patients with advanced metastatic cancer at a single administration of up to 1x1013 Viral Particles (VPs). Notably, tumor response and superior overall survival were found in the 1x1013 VPs cohort compared to sub-therapeutic doses. The data confirm pre-clinical findings in animal models and validate VB-111's mechanism of action, resulting in a targeted expression of the FAS-chimera transgene selectively in tumor vasculature.
Help employers find you! Check out all the jobs and post your resume.
comments powered by